Peregrine Pharma (PPHM) Misses Q1 EPS by 1c

Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.05), $0.01 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $5.61 million versus the consensus estimate of $13.09 million.

GUIDANCE:

Peregrine Pharma sees Q2 2017 revenue of $20 million, versus the consensus of $12.5 million.

• Company Reaffirms Revenue Projection of $50 - $55 Million for Full FY 2017 with Growing Backlog of Business

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Movano (MOVE) Misses Q2 EPS by 195c